EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of chronic trypanosomiasis on the bioavailability of alpha -difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay






Parasitology Research 83(4): 386-389

Effect of chronic trypanosomiasis on the bioavailability of alpha -difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay

A method for detecting alpha -difluoromethylornithine (DFMO) in plasma during pharmacokinetic studies in mice is described, using conventional reversed-phase HPLC with UV detection. It was shown that mice infected with Trypanosoma brucei had Cmax values 2-fold higher than those of non-infected mice. It is concluded that pharmacokinetic studies should compare both infected and naive subjects.

(PDF 0-2 workdays service: $29.90)

Accession: 002811061

PMID: 9134564



Related references

Effect of chronic trypanosomiasis on the bioavailability of α-difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay. Parasitology Research 83(4): 386-389, 1997

Pharmacokinetics pk of alpha difluoromethylornithine dfmo and levels of polyamines in patients pts receiving dfmo in a phase i chemoprevention study. Proceedings of the American Association for Cancer Research Annual Meeting 31: 182, 1990

Studies on lipidomimetic derivatives of alpha-difluoromethylornithine (DFMO) to enhance the bioavailability in a Trypanosoma B. brucei murine trypanosomiasis model. Parasite 5(3): 239-246, 1998

Functional consequences of polyamine synthesis inhibition by L-alpha-difluoromethylornithine (DFMO): cellular mechanisms for DFMO-mediated ototoxicity. Journal of Biological Chemistry 280(15): 15097-15102, 2005

Antitumor effect of alpha-difluoromethylornithine (DFMO) changes in ornithine decarboxylase (ODC) activity and polyamine (PA) levels in human tumor transplanted into nude mice. Nihon Geka Gakkai Zasshi 90(5): 650-660, 1989

Chemotherapy of CNS-trypanosomiasis: the combined use of diminazene aceturate or pentamidine with DL-alpha-difluoromethylornithine (DFMO). Tropical Medicine and Parasitology 43(2): 106-109, 1992

Studies on the efficacy of DL-alpha-difluoromethylornithine (DFMO) associated with bleomycin and suramin for treatment of mice infected with metacyclic forms oftrypanosomabruceibrucei. Veterinary Research Communications 11(3): 271-274, 1987

Towards more efficacious chemotherapy of trypanosomiasis: combination of alpha-difluoromethylornithine (DFMO) with reactive oxygen generating drugs. Medical Hypotheses 36(3): 246-249, 1991

New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin. American Journal of Tropical Medicine and Hygiene 33(6): 1073-1077, 1984

Functional Consequences of Polyamine Synthesis Inhibition by L--Difluoromethylornithine (DFMO): CELLULAR MECHANISMS FOR DFMO-MEDIATED OTOTOXICITY. Journal of biological chemistry15 280(15): 15097-15102, 2005